Board of Trustees

An analytical chemist who spent two decades developing and validating stability-indicating methods for peptide and protein products. She is the principal author of the Institute's COA minimum data standard and of the…

A pharmacist and clinical pharmacologist whose research concerns medication safety in populations obtaining medicines outside regulated supply. He argued successfully that the Institute should publish supplier dossiers…

A public-health physician with a background in evidence appraisal for population-level commissioning. Her contribution to the Institute's framework is the requirement that every assessment state the population in which…

Responsible for ensuring that the Institute's comment periods are genuinely open to people who use the compounds it assesses, rather than only to professionals. She has argued, against some internal resistance, that a…

Responsible for the Institute's finances and for the sponsorship-disclosure architecture. She established the rule that no sponsor may exceed twenty per cent of annual income and that any sponsor whose contribution…

A clinical pharmacologist whose career was spent in regulatory assessment and in the methodology of benefit–risk evaluation. She chaired a national medicines committee for nine years and has written extensively on the…

A hepatologist whose clinical research concerns metabolic dysfunction-associated steatotic liver disease and the reliability of histological endpoints. She led the Institute's decision to record, for every histological…

A lawyer whose practice concerned regulatory and research-integrity matters. He designed the Institute's conflicts-of-interest regime, including the rule that a declared interest in a compound removes a reviewer from…